Can radiation start before a cancer biopsy? trial tests a faster path for patients in pain

NCT ID NCT06156800

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 02, 2026 · Last updated Oct 02, 2026

Summary

Doctors usually wait for biopsy results before giving radiation, but that wait can be long and painful for patients with advanced cancer. This trial tests whether giving palliative radiation first, before a biopsy confirms cancer, is safe and practical for a carefully selected group of adults who need urgent symptom relief. Researchers will track how often the radiation turns out to have been inappropriate once biopsy results arrive, and whether biopsies taken from radiated areas still give accurate diagnoses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palliative radiation therapy delivered before a biopsy
What this could lead to
If it works, this approach could let patients with urgent cancer symptoms start radiation sooner instead of waiting weeks for biopsy results.
What could go wrong
This is a small, early-phase feasibility trial, so it cannot prove the approach is safe or effective. Some patients might receive radiation for a non-cancerous condition, or the biopsy might not yield a clear diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with convincing clinical/radiological evidence of cancer, ineligible for curative treatment and awaiting a biopsy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Willing to provide informed consent * Palliative treatment intent: either metastatic or incurable locally advanced disease * Tissue diagnosis is not required for determination of dose/fractionation scheme * Recent cross-sectional imaging \[for example - Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography/Computed Tomography (PET/CT)\] of the area to be treated, done within the past 3 months * Treating physician considers the pre-test probability of cancer greater than 95 percent based on clinical judgement and radiological findings. * The patient has at least 1 site of cancer amenable to biopsy * As per standard practices, if the radiation oncologist will be radiating the only site available to biopsy, they should proceed with caution. Participants should only be enrolled on trial if the risk of harm from delaying Radiation Therapy (RT) significantly outweighs the risks of possible non-diagnostic tissue. If the participant may potentially be eligible for systemic therapy, the treating radiation oncologist should consult a medical oncologist for an opinion regarding the risks of non-diagnostic molecular testing. The weighing of these priorities should be thoroughly discussed with the participant and the discussion should be documented. * Reasons for radiating a participant with a single lesion prior to biopsy include: * Spinal cord compression (actual or impending) and inoperable * Brain metastasis with significant symptoms or neurologic deficits and inoperable * Other lesions causing neurologic deficit * Pulmonary lesion causing or threatening lung obstruction * Uncontrolled bleeding (including hemoptysis and hematuria) * Superior vena cava obstruction (actual or impending) * Limited upside to molecular testing, as determined by the medical oncologist (for example - participant unfit for available systemic therapies, limited options for systemic therapy) * Radiation is considered urgent (for example - participant should receive radiation prior to biopsy date) o Urgent indications may include but are not limited to the reasons listed previously, as well as the following: * Painful metastases or primary lesion not adequately responding to analgesia * Symptomatic brain metastases * Bleeding * Impending pathologic fracture Exclusion Criteria: * Participant is potentially eligible for curative treatment * Clinical suspicion of lymphoma o Some features may be suggestive of lymphoma, including fever or night sweats (for example - B symptoms excluding weight loss), or imaging showing well-defined, homogenous lymphadenopathy. These findings are not exclusion criteria specifically, but should be considered by the clinician in formulating their differential diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • London Regional Cancer Program, London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.